Empowering women to break the status quo on hormonal birth control.

Market Opportunity

Evofem is Leading a New Era in Women’s Contraception Targeting a Multi-Billion Dollar Market Opportunity

  • Phexxi net sales increased in the third quarter of 2022 for the fourth consecutive quarter.
  • Net product sales had already surpassed 2021 levels in the first half of 2022.  
  • Payers and pharmacy benefit managers (PBMs) continue to add Phexxi to their formularies, allowing women to fill their prescriptions immediately.
  • Updated guidelines from the U.S. Department of Labor and Health Resources and Services Administration (HRSA) took effect on January 1, 2023, for calendar year plans. These guidelines clarify that most group health plans and insurers must cover FDA-approved contraceptives, including Phexxi, at no cost to individuals under the Affordable Care Act (ACA)
  • Partnership discussions are ongoing for the commercialization of Phexxi in international markets.

Read Our Latest Press Releases

A Paradigm Shift in Contraception

23M+ women in the U.S. are not using a hormonal contraceptive.2

As the organic movement grows, society is trending in favor of more natural products and solutions. Women’s healthcare is no different. Many women are now opting for a non-hormonal, localized method of birth control. 

Because Phexxi is a non-hormonal birth control, it is not associated with side effects like depression, mood swings and irritability. With Phexxi, women do not need to choose between their quality of life or contraception.

Taking hormones may not be right for some women especially for those with certain medical conditions including clotting disorders and most cancers, limiting their birth control options. There are approximately 800,000 new cases of cancer reported annually among women.3  Phexxi uniquely offers hormone-free, non-invasive prescription contraception.

23M+ Women in
the U.S. are not
using a Hormonal Contraceptive.


1 https://www.guttmacher.org/sites/default/files/factsheet/fb_iaw.pdf

2 Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14.

3 https://www.cdc.gov/cancer/uscs/about/data-briefs/no17-USCS-highlights-2017-incidence.htm